Skip to main content
    K

    Kiniksa Pharmaceuticals Ltd (KNSA)

    Official site

    HEALTHCARE • DRUG MANUFACTURERS - SPECIALTY & GENERIC • NASDAQ

    $94.23
    -2.10 (-2.18%)

    Market Cap: $7.57B

    Last updated: Nov 17, 2026 at 11:06 AM ET

    Kiniksa Pharmaceuticals Ltd (KNSA) P/E Ratio & Valuation History

    Updated Nov 17, 2026. Multiples are computed from end-of-day prices, company filings and consensus analyst estimates.

    Kiniksa Pharmaceuticals (KNSA) trades at 72.5x trailing earnings and 7.8x sales. Its P/S of 7.8x is above its 5-year median of 4.7x. Its forward P/E is 60.6x. The median P/E across 10 similar companies is 19.9x.

    Current Multiples

    Its forward P/E is below its trailing P/E, which implies earnings per share about 19.6% higher over the next year. Its free cash flow yield is 2.7%.

    MultipleValue
    P/E (trailing)72.5x
    Forward P/E60.6x
    Price to sales7.8x
    Price to book10.4x
    EV/EBITDA49.2x
    Price to FCF37.4x
    EV/FCF36.9x
    PEGN/A
    FCF yield2.7%
    As of Nov 17, 2026

    Historical Medians

    Against its 10-year medians, its P/B is 188.9% above 3.6x.

    MultipleCurrent5-year median10-year median
    P/S7.8x4.7xN/A
    P/B10.4x3.8x3.6x
    Medians of month-end values through Oct 2026: 60 months (5-year) and 102 months (10-year).

    Valuation History

    Over the 3 of the 8 year ends shown that have a P/E, its P/E ranged from 5.8x in 2022 to 97.4x in 2023.

    Year endPriceP/EP/SP/B
    2025$41.2555.7x4.6x5.7x
    2024$19.78N/A3.3x3.3x
    2023$17.5497.4x4.6x2.9x
    2022$14.985.8x4.8x2.7x
    2021$11.77N/A21.0x4.4x
    2020$17.67N/AN/A3.9x
    2019$11.06N/AN/A2.7x
    2018$28.09N/AN/A4.9x
    Each year's multiples use the split-adjusted closing price of that year's last trading day over trailing per-share results as reported; periods with losses are left out.

    GNG Valuation

    GNG viewOvervalued

    GNG fair value is part of GNG Pro. See plans

    Frequently Asked Questions About KNSA

    What is KNSA's forward P/E ratio?

    Kiniksa Pharmaceuticals has a forward P/E ratio of 60.6x.

    Is KNSA stock overvalued?

    GNG's valuation label for KNSA is Overvalued. Its P/E of 72.5x compares with a median of 19.9x across 10 similar companies.

    What is KNSA's price to sales ratio?

    Kiniksa Pharmaceuticals has a price to sales ratio of 7.8x.